| Project/Area Number |
23701109
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Chiba Cancer Center (Research Institute) |
|---|
Principal Investigator |
HASEGAWA Yuzo 千葉県がんセンター(研究所), 医療局 脳神経外科, 医長 (60436409)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | Oncolytic virus / Glioblastoma / dendritc cells / gene therapy / immunotherapy / 腫瘍融解ウイルス / 悪性脳腫瘍 / 樹状細胞 / 遺伝子治療 / 免疫治療 / ウイルス治療 / 抗腫瘍ウイルス / 脳腫瘍 |
|---|
| Outline of Final Research Achievements |
Malignant brain tumor is highly invasive and intractable. Urokinase-targeted oncolytic Sendai virus vector, “BioKnife”, is one of promissing new therapeutic tools that possesses powerful oncolytic ability, we previously reported. We examined for immunological effects of this BioKnife armed interferon β, “BioKnife-IFNβ” in this study. Dendritic cells secreted high level of tumor necrotic factor α and interleukin-12 when they were cultured with 9L tumor cells infected by BioKnife, especially BioKnife-IFNβ. Rat malignant brain tumor cell line, 9L, is usually expresses low level of major histocompatibility complex class I and expression of this antigen was increased by BioKnife, especially BioKnife-IFNβ. This effect was not only observed in infected tumor cells but also non-infected cells, interestingly. Induction of cytotoxic T cells was actually detected in rats bearing brain tumor treated with BioKnife-IFNβ. This immuno-modulating BioKnife-IFNβ is very promising.
|
